Altmetric

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.

File Description SizeFormat 
Claudiani S et al - Haematologica 2017.pdfPublished version181.96 kBAdobe PDFView/Open
Title: E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.
Authors: Claudiani, S
Apperley, J
Gale, RP
Clark, R
Szydlo, R
Deplano, S
Palanicawandar, R
Khorashad, J
Foroni, L
Milojkovic, D
Item Type: Journal Article
Issue Date: 11-May-2017
Date of Acceptance: 1-May-2017
URI: http://hdl.handle.net/10044/1/49044
DOI: https://dx.doi.org/10.3324/haematol.2017.168740
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation
Start Page: e297
End Page: e299
Journal / Book Title: Haematologica
Volume: 102
Issue: 8
Copyright Statement: © 2017 Ferrata Storti Foundation. Haematologica August 2017 102: e297-e299; Doi:10.3324/haematol.2017.168740. Open Access under the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/)
Sponsor/Funder: Imperial College Trust
Imperial College Healthcare NHS Trust- BRC Funding
National Institute for Health Research
Imperial College Healthcare NHS Trust
Funder's Grant Number: 070904JA
RDB05 79560
NF-SI-0611-10275
IPH-RMO-HH/004
Keywords: Chronic Myelogenous Leukemia
Chronic Myeloproliferative Disorders
Minimal Residual Disease
Stopping TKI
Treatment free remission
Immunology
1102 Cardiovascular Medicine And Haematology
Publication Status: Published
Conference Place: Italy
Appears in Collections:Department of Medicine
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons